Enhancing Recovery and Reducing Inflammation: The Impact of Enhanced Recovery After Surgery Recommendations on Inflammatory Markers in Laparoscopic Surgery – a Scoping review

Carlos Darcy Alves Bersot^{1,2}, Lucas Ferreira Gomes Pereira^{1,3}, Victor Gabriel Vieira Goncho^{1,2}, José Eduardo Guimaraes Pereira⁴ and Luiz Fernando dos Reis Falcão^{1,5}

- 1. Department of Anesthesia, BP Hospital A Beneficência Portuguesa de São Paulo (Anextesia), São Paulo, Brazil.
- 2. Postgraduate in Translational Medicine of the Paulista School of Medicine, EPM-UNIFESP, São Paulo, Brazil
- Discipline of Anesthesiology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
- 4. Department of Anesthesiology, Hospital Unimed Volta Redonda, Rio de Janeiro, Brazil.
- 5. Department of Anesthesiology, Pain and Critical Care Medicine, Federal University of São Paulo (EPM-UNIFESP), São Paulo, Brazil.
 - * Correspondence: Author: Luiz Fernando dos Reis Falcão, falcao@unifesp.br

ABSTRACT: Introduction: The relationship between the Enhanced Recovery After Surgery (ERAS) guidelines and inflammatory markers in laparoscopic surgery has garnered increasing attention. These recommendations are designed to minimize surgical stress and potentially improve recovery outcomes by modifying perioperative care. Objective: This scoping review aims to evaluate the impact of ERAS recommendations on inflammatory markers in patients undergoing laparoscopic surgeries, identifying current research gaps and consolidating findings from existing studies. Methods: Guided by the Cochrane Handbook for Systematic Reviews and adhering to the PRISMA-ScR guidelines, this review analyzed studies from databases like PubMed, Scopus, and Cochrane Library. We included both randomized controlled trials and observational studies that assessed inflammatory markers such as C-reactive protein (CRP), white blood cells (WBC), and Interleukin-6 (IL-6) in laparoscopic surgery patients managed with ERAS recommendations. Results: Out of 64 initial studies, 7 met the inclusion criteria, involving a total of 2,047 patients. Most of the studies focused on laparoscopic colorectal surgeries. Commonly assessed markers were CRP and WBC. The findings consistently showed that ERAS guideline could mitigate the inflammatory response, evidenced by reduced levels of CRP and IL-6, which correlated with fewer postoperative complications and expedited recovery. Conclusion: ERAS recommendations appear to beneficially modulate inflammatory responses in laparoscopic surgery, which suggests a potential for enhanced recovery outcomes. However, the evidence is currently limited by the small number of studies and inherent methodological biases. Further robust RCTs are required to strengthen the evidence base and refine these protocols for broader clinical application.

Keywords: Enhanced Recovery After Surgery; Inflammation; Laparoscopy.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

INTRODUCTION

The association between inflammation and cancer has been extensively discussed since 1863, when Virchow observed that tumors frequently develop at sites of chronic inflammation.⁽¹⁾ Research has consistently demonstrated that inflammation contributes to tumor growth and aggressiveness; both preoperative and early postoperative inflammatory responses can foster a micrometastatic environment and adversely affect cancer prognosis. ⁽¹⁻⁴⁾

The initiative to reduce recovery times after surgery was pioneered in the USA under the concept of "fast-track" surgery, particularly aimed at expediting recovery following cardiac procedures. (5) Kehlet et al. further advanced this concept by developing a multimodal rehabilitation program focused on colorectal surgeries, which was successful in reducing hospital stay durations. (6) The Enhanced Recovery After Surgery (ERAS) programs have refined these preliminary concepts into a standardized, evidence-based approach that enhances surgical outcomes across various disciplines. Originating in Europe, ERAS Society unites diverse surgical teams dedicated to fostering comprehensive, multiprofessional patient care. (7)

The cellular response to surgical tissue damage triggers the activation of macrophages and neutrophils within the innate immune system via the production of inflammatory cytokines, such as tumor necrosis factor (TNF) alpha, interleukin (IL)-1, and IL-6. These proinflammatory cytokines modify the levels of circulating acute-phase proteins, including C-reactive protein (CRP), albumin, ferritin, transferrin, and fibrinogen. (8) However, the pathophysiology of post-surgical recovery is not solely a consequence of tissue injury but is inherently multifactorial, encompassing elements such as anxiety, pain, coagulation disorders, hemodynamic changes, and hypoxia. Given the multitude of factors that promote inflammation during the surgical stress response, interventions proposed by the ERAS guidelines address these various components comprehensively. (9)

This scoping review aims to provide a descriptive summary of the studies included and to identify potential gaps in the literature regarding the impact of the ERAS guidelines on the inflammatory response following laparoscopic surgery. The guiding question for this review is: "What research has been conducted on the impact of the ERAS

recommendations on inflammatory markers in laparoscopic surgery, and what evidence is available regarding its effects on the immune system?"

METHODS

Study Design and Protocol Registration

This scoping review was guided by the Cochrane Handbook for Intervention Reviews (10) and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extensions for Scoping Reviews (PRISMA-ScR).(11) The research protocol was registered on the Open Science Framework (https://osf.io/ti8mw/).

Eligibility Criteria

We included randomized controlled trials and observational studies assessing the impact of the Enhanced Recovery After Surgery (ERAS) recommendations on inflammatory markers in patients undergoing laparoscopic surgery. Eligible participants were adults aged 18 years or older who underwent any type of laparoscopic surgery and had one or more of the following inflammatory biomarkers measured: C-reactive protein (CRP), white blood cell count (WBC), immunoglobulins (IgG and IgA), tumor necrosis factor (TNF), total protein (TP), cortisol, among others.

The intervention study groups will be considered those adopting any series of measures aimed at optimizing and accelerating recovery in the perioperative period, while the control group will be considered the population with traditional perioperative care. Both nomenclatures will be considered for the intervention group, both ERAS and Fast-track will be accepted.

Data Sources and Search Strategy

The literature search was conducted using PubMed (MEDLINE), Scopus, Embase, Web of Science, and the Cochrane Controlled Register of Trials (CENTRAL). We also searched for unpublished studies and gray literature through manual searches of reference lists of included articles. The initial search was performed in January 2024, with a follow-up search in February 2024. Searches employed combinations of MeSH terms and their synonyms including "Enhanced Recovery After Surgery," "Inflammation," and "Laparoscopy." Our search strategies, adapted for each database, are detailed in Appendices I and II. No restrictions were placed on language or publication date.

Study Selection

Three reviewers (VGVG, LFGP, CDAB) independently screened titles and abstracts using a standardized screening protocol. Full texts of potentially relevant studies were retrieved, and their details uploaded into Rayyan® (Qatar Computing Research Institute, Doha, Qatar). Disagreements among reviewers were resolved through discussion or consultation with a third party (JEGP, LFRF).

Data Extraction and Risk of Bias Assessment

Data were extracted independently by the same four reviewers using a specially developed form. Extracted information included publication year, country, study type, surgical type, population characteristics, ERAS recommendations details, inflammatory markers, and pertinent findings. Authors were contacted to resolve data discrepancies or clarify missing details.

Risk of bias was assessed using the Guyatt-modified Cochrane approach for randomized trials (13, 14) and the Morgan approach for non-randomized studies. (15) The criteria for randomized trials included adequacy of random sequence generation, allocation concealment, blinding (of investigators, patients, data collectors, statisticians, outcome assessors), completeness of outcome data, and absence of selective reporting. A threshold of less than 10% total loss to follow-up was considered low risk. Non-randomized studies were assessed for eligibility criteria, outcome and exposure measurement accuracy, confounder control, and follow-up adequacy.

Data Analysis and Presentation

Data were synthesized and displayed in two tables highlighting the characteristics of the ERAS recommendations and the inflammatory markers assessed. Details such as publication year, country, study type, surgical type, ERAS details, and outcomes were tabulated. If the outcomes found and summarized in the results are amenable to quantitative analysis, they will be analyzed by means of a meta-analysis, divided into different outcomes.

RESULTS

Search Results and Study Selection

Our systematic database search initially identified 64 studies. After removing 9 duplicates, 55 records were screened by title and abstract, with 43 subsequently excluded. Full texts of the remaining 12 studies were evaluated for eligibility, resulting in 5 further exclusions. Ultimately, 7 studies met our inclusion criteria. The selection process is depicted in the PRISMA flowchart (Figure 1).




Figure 1. - PRISMA Flowchart.

Characteristics of Included Studies

The included studies were published between 2012 and 2022. Four of these were randomized clinical trials, and three were non-randomized observational studies (Table 1). The studies involved both male and female participants, with the ERAS group having a mean age of 59.7

years-old compared to 49.7 years-old in the control group. Geographically, four studies were conducted in China (16-19), one in Italy⁽²⁰⁾, and one in South Korea ⁽²¹⁾ (Table 2). The surgical interventions examined included colorectal surgeries(16-18, 20, 21), gastrectomy(19), and gynecological oncological surgery(22).

Table 1. - Study characteristics according to population and type of publication.

Authors	Year and Country	Type of study	Type of surgery	
Xu et al.	2015, China	Randomized Controlled Trial	Colorectal laparoscopic	92 patients
Wang et al.	2012, China	Randomized Controlled Trial	Colorectal laparoscopic	163 patients
Tian et al.	2020, China	Retrospective cohort	Laparoscopic Gastrectomy	1026 patients
Peng et al.	2021, China	Randomized Controlled Trial	Gynecological Oncology	130 patients
Mari et al.	2016, Italy	Randomized Controlled Trial	Colorectal laparoscopic	140 patients
Liu et al.	2020, China	Retrospective cohort	Colorectal laparoscopic	200 patients
Jalloun et al.	2020, South Korea	Retrospective cohort	Colorectal laparoscopic	296 patients

Author	Country/ Year	n participa nts included	mean age per study group	Male gender per group	Inclusion criteria	Exclusion criteria	Follow- up time
Jalloun et al.	2020, South Korea	296 patients I-82 C-214	I-< 65 37 (45.1)≥ 65 45 (54.9) C- < 65 100 (46.7) < 65 114 (53.3)	I-44 C-127	All patients with diagnostic colonic cancer		4 days
Liu et al.	2020, China	200 patients I-100 C-100	I-68.49 C-65.95	I-57 C-48	1) pathologically confirmed CRC, 2) treated with one-stage radical resection (excluding Miles procedure) by the same group of doctors; 3) good nutritional status, 4) no significant heart, lung, kidney, or other important organ dysfunction; 5) no distant lumor metastasis; 6) no previous abdominal surgery; 7) no radiotherapy or chemotherapy; and 8) anesthesia ASA score < 4 points.	1) patients with such intestinal as obstruction or perforation requiring immediate surgery; 2) severe malnutrition; 3) poor mobility; 4) anesthesia ASA score > 4 points; and 5) mental illness.	9 hours

Mari et al.	2016, Italy	140 patients I-70 C-70	I- 64 (42- 83) C- 67 (39-87)	I-39 C-35	Patients between 18 and 80 years of age, with American Society of Anesthesiolo gists grades I through III, autonomous for mobilization and walking, eligible for laparoscopic technique		5 days
Xu et al.	2015, China	92 patients I-46 C-46	I-59.3 ± 12.5+59. 1±9.8/2 C-58.0 ± 13.2+60. 8±7.6/2	I-29 C-28	1) American Society of Anesthesiol ogists (ASA) grades I-III (no life-threatening systemic diseases) 2) Age ≥18 years old 3) With pathological ly confirmed colon and upper rectal cancer.	Patients are younger than 18 years 2) ASA grade ≥ IV 3) Preopera tive evidence of distant metastas es 4) History of malignan t disease 5) Tumors can be resected by endosco pic mucosal resection (EMR) or endosco pic submuco sal dissectio n (ESD), bowel obstructi on or perforatio n, and patients	4 days

						undergoi ng total colectom y, mid- low rectal cancer, and pregnanc y.	
Wang et al.	2012, China	163 patients I-81 C-82	I-56 C-58	I-51 C-51	The inclusion criteria were as follows: no disease of the immune system; no preoperative radiotherapy or chemothera py; no history of operation on abdominal and distant metastases; American Society of Anesthesiol ogy (ASA) score: degree I–III; and self-care function prior to hospitalizati on.	The exclusion criteria were as follows: as-sociation with other organ resection / conversio n from laparosc opic operation to laparoto my, inability to place an epidural catheter, inability to infuse drugs, and emergen cy operation .	Blood sample s were obtaine d on the day before operatio n, as well as on days 1, 3, and 5 after operatio n.
Tian et al.	2020, China	1026 patients	I- 59.6 C-59.4	I-279 C-298	-	After excluding some patients who did not meet the criteria	
Peng et al.	2021, China	130 patients	I-47,4 C-43.53	I-0 C-0	Patients	-had a	6 months

I-65 C-65	between the age of 18-70 years, who were diagnosed with cervical tumors, uterine tumors or ovarian tumors, were eligible for enrollment.	constipati on and

Table 2. - Study characteristics related to population and setting.

Authors and Year	Type of surgery	Groups studied	ERAS protocol	Inflammatory markers	Results
Jalloun et al., 2020	Colorectal laparoscopy	ERAS protocol group (EP) and Control protocol group (CP).	Preoperative: patient education, oral carborydrake treatment, formula intake, shrombosis prophylaxis, antibiotics prophylaxis. Intracperative: Epidural or spinal anesthesia, body temperature preservation, restrictive fluid strategy, PONV prophylaxis. Postoperative: Epidural analgesia, effective pain control, balanced fluids, stimulation of gut motility, termination of Iv fluid influsion, mobilization, and energy intake.	White blood count/ WBC); C-reactive protein level; alturnia tevel; neutrophil/hymphocyte ratio (NLR), and the time required after surgery for the leukocyte count to drop below 10,000/mm3 in days.	Increased WBC count: EP = 42,7%, CP = 72,9; Time required for the WBC count to normalize was significantly shorter in the EP group than in the CP group (Ps0.001). C-reactive protein level: EP = 24,1%; CP = 80,6% (P< 0.001).
Liu et al., 2020		Traditional treatment (TT) and ERAS group (EG).	Preoperative: patient education, jestrointestinal preparation. Intraoperative: Body temperation, intraoperative: Body temperative, liquid management (esophageal doppler ultrasound). Postoperative: Analgesia (continuous epidural), catheter indiveiling, sarty enteral nutrition and early activities.	The blood was collected 24h before surgery, to obtain the preoperative NLR. Another blood sample was collected on the postoperative day 3 to calculate NLR. Total protein (TP) and albumin (alb) were also analysed.	Preoperative NLR: TT = 2.86 ± 0.98; EG = 3.03 ± 0.92; Postoperative NLR: TT = 3.71 ± 0.86; EG = 3.22 ± 0.85; Preoperative TP: TT = 71.40 ± 5.36; EG = 70.09 ± 6.12; Postoperative TP: TT = 52.92 ± 1.73; EG = 57.82 ± 2.27; Preoperative aib: TT = 45.78 ± 3.87; EG = 44.94 ± 3.80. Postoperative aib: TT = 32.83 ± 1.89; EG = 37.07 ± 1.46.

Mari et al., 2016	ERAS gro	p Preoperative: Bowel preparation, 200	The blood was collected	Preoperative CRP: EG = 6.2 ± 8.9; SG
	(EG) and	mL oral maltodextrin intake 6 and 2 h	preoperatively, 1, 3 and 5 days	14.1 ± 16.4; Day 1 CRP: EG = 50.9 ±
	Standard gr	oup before surgery. Intraoperative: Fluid	after surgery. Cortisol,	14.5; SG = 93.2 ± 11.3; Day 3 CRP: E
	(SG).	restriction (5-10 mL/kg/h), Nasogastric	C-reactive protein (CRP), WBC	= 53.2 ± 13.1; SG = 89.8 ± 14.6; Day
		tube removal. Postoperative: Spinal	count, interleukin (IL)-6;	CRP: EG = 36.3 ± 19.5; SG = 78.6 ±
		analgesia and opioid and NSAID oral,		10.3. Preoperative WBC: EG = 6486 :
		fluid management (1500 mL/d), fluid		2353; SG = 6472 ± 1821; Day 1 WBC
		meal after 6h and solid meal after 24h		EG = 9717 ± 2869; SG = 9598 ± 2950
		and mobilization 6h after surgery.		Day 3 WBC: EG = 8325 ± 2706; SG =
				8947 ± 2943; Day 5 WBC: EG = 6670
				2317; SG = 7321 ± 2349. Preoperative
				IL-6: EG = 11.3 ± 6.9; SG = 6.3 ± 9.1;
				Day 1 IL-6: EG = 20.6 ± 8.2; SG = 39.2
				12.1; Day 3 IL-6: EG = 17.8 ± 9.9; SG
				41.8 ± 12.4; Day 5 IL-6: EG = 14.3 ± 8.
				SG = 35.9 ± 10.3. Preoperative cortiso
				EG = 16.6 ± 6.3; SG = 16.5 ± 5; Day
				cortisol: EG = 12.8 ± 7.8; SG = 15.9 :
				9.4; Day 3 cortisol: EG = 19 ± 9.2; SG
				19.6 ± 7.6. Day 5 cortisol: EG = 17.4 :
				6.96; SG = 21 ± 8.7.
Xu et al., 2015	Laparosco	py Preoperative: Oral carbohydrates	The blood samples were	Preoperative IgG: LAFT =91.6 (10.5)
	with fast-tra	ck before surgery. Intraoperative: Fluid	collected preoperatively, 12	LAC 90.2 (10.1); 12h lgG: LAFT = 88.
	treatmen	restriction, body warming.	hours and 96 hours after	(72.6-101.2); LAC = 87.6 (72.0-101.3
	(LAFT);	Postoperative: early oral nutrition, early	surgery. IgG, IgM, IgA, T and NK	96h lgG: LAFT = 94.9 (80.1-121.7); L/
	Laparosco	24	cells were evaluated.	= 92.7 (70.8-109.0). Preoperative lg/

		with	ambulation and early removal of		LAFT = 93.4 (11.6); LAC = 92.1 (11.3)
		conventional	nasogastric tube.		12h IgA: LAFT = 88.7 (70.3-120.8); LA
		treatment			= 88.6 (74.3-106.3); 96h lgA: LAFT :
		(LAC);			98.2 (80.1-115.7); LAC = 95.5
		,,-			(73.3-111.6), Preoperative IgM: LAFT
					90.3 (17.6): LAC = 90.2 (34.2): 12h lg
					LAFT = 87.6 (49.0-116.0); LAC = 85
					(36.9–113.7); 96h IgM: LAFT = 93.1
					(64.6-145.9); LAC = 95.1 (34.5-271.2
					Preoperative T cells: LAFT = 94.7 (16.
					LAC = 95.4 (20.9); 12h T cells: LAFT
					86.8 (57.6-128.3); LAC = 84.6
					(53.8-103.4); 96h T cells: LAFT = 103
					(79.5-126.0); LAC = 106.2 (57.5-152
					Preoperative NK cells: LAFT = 122.
					(57.2); LAC = 119.5 (44.4); 12h NK ce
					LAFT = 147.7 (39.8-324.3); LAC = 13
					(90.2-246.0), 96h NK cells; LAFT = 9
					(50.9-158.5); LAC = 102.1 (43.4-188
Wang et al.,2012		Fast-track	Preoperative: no bowel preparation,	The blood samples were	Preoperative CRP: FTL = 4.83 ± 3.7
		laparoscopic	10% glucose injection orally	collected on the preoperative,	TL = 4.48 ± 3.05; CRP Day 1: FTL
		group (FTL);	administered; intake of oral fluids until	post-operative day 1, day 3 and	60.52±19.1; TL = 87.21±16.05; CRP I
		Traditional	2h before initiation of surgery and 6h	day 5. The inflammatory	3: FTL = 84.45±15.31; TL =
		protocol	fast for solid food, Intraoperative:	markers analysed were: Serum	99.55±14.46; CRP Day 5: FTL =
		laparoscopic	General anesthesia with epidural	C-reactive protein (CRP) levels.	54.65±15.03; TL = 72.85±14.95.
		group (TL).	catheter, no surgical drains.	IL-6, CD3; CD4 and CD4/CD8	Preoperative IL-6: FTL = 19.82 ± 8.1
		group (TE):	Postoperative: Use of epidural catheter,	ratio.	TL = 19.16 ± 8.14; IL-6 Day 1: FTL
			discard urinary catheterization within		
			24h, early deambulation and free fluids		Day 3: FTL = 70.58±12.13; TL =
			24h, early deambulation and free fluids on the operation day, followed by		Day 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 5: FTL =
			24h, early deambulation and free fluids		Day 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 5: FTL = 45.65±8.25; TL = 60.43±10.54.
			24h, early deambulation and free fluids on the operation day, followed by		Day 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 5: FTL = 45.65±8.25; TL = 60.43±10.54. Preoperative CD3: FTL = 55.21±2.7
			24h, early deambulation and free fluids on the operation day, followed by		Day 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 5: FTL = 45.65±8.25; TL = 60.43±10.54. Preoperative CD3: FTL = 55.21±2.7 TL = 55.15±2.65; CD3 Day 1: FTL
			24h, early deambulation and free fluids on the operation day, followed by		Day 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 5: FTL = 45.65±8.25; TL = 60.43±10.54. Preoperative CD3: FTL = 52.51 ± 2. TL = 55.15 ± 2.65; CD3 Day 1: FTL 47.81 ± 3.27; TL = 46.13 ± 2.13; CD
			24h, early deambulation and free fluids on the operation day, followed by		Day 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 5: FTL = 45.65±8.25; TL = 60.43±10.54. Preoperative CD3: FTL = 55.21±2.: TL = 55.15±2.65; CD3 Day 1: FTL 47.81±3.27; TL = 45.13±2.13; CD Day 3: FTL = 50.35±3.02; TL = 47.6
			24h, early deambulation and free fluids on the operation day, followed by		Day 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 5: FTL = 45.65±8.25; TL = 90.43±10.54. Preoperative CO3: FTL = 55.21±2.1 TL = 55.15±2.65; CD3 Day 1: FTL 47.91±3.27; TL = 46.13±2.13; CD 30y 3: FTL = 50.35±3.02 TL = 42.24; CD3 Day 5: FTL = 51.92±2.25
			24h, early deambulation and free fluids on the operation day, followed by		Day 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 5: FTL = 45.65±8.25; TL = 60.43±10.54. Preoperative CO3: FTL = 56.21±2.1 TL = 55.15±2.65; CD3 Day 1: FTL 47.81±3.27; TL = 46.13±2.13; CD Day 3: FTL = 50.35±3.02; TL = 47.62±3.42; CD3 Day 5: FTL = 51.9±2.265 = 49.21±2.29; Preoperative CD4: FT
			24h, early deambulation and free fluids on the operation day, followed by		Day 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 5: FTL = 45.65±8.25; TL = 60.43±10.54. Preoperative CO3: FTL = 56.21±2.1 TL = 55.15±2.65; CD3 Day 1: FTL 47.81±3.27; TL = 46.13±2.13; CD Day 3: FTL = 50.35±3.02; TL = 47.62±3.42; CD3 Day 5: FTL = 51.9±2.265 = 49.21±2.29; Preoperative CD4: FT
			24h, early deambulation and free fluids on the operation day, followed by		Dey 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 6: FTL = 45.65±6.5; TL = 60.43±10.54. Preopensive CD3: FTL = 56.21±2.3 TL = 55.15±2.65; CD3 Day 1: FTL - 47.8±13.27; TL = 46.13±2.75; TL = 45.13±2.25 Day 3: FTL = 50.35±3.02; TL = 47.8±2.25 49.21±2.29; Preoperative CD4: FTL = 49.21±2.29; Preoperative CD4: FTL = 33.92±3.59; CD
			24h, early deambulation and free fluids on the operation day, followed by		Day 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 5: FTL = 45.65±8.25; TL = 60.43±10.54. Preoperative CO3: FTL = 55.21±2. TL = 55.15±2.65; CD3 Day 1: FTL 47.61±3.27; TL = 46.13±2.13; CD Day 3: FTL = 50.35±3.02 TL = 47.61±2.23; CD3 Day 5: FTL = 51.92±2.65 = 492.21±2.29; Preoperative CO4: FT = 33.02±3.22; TL = 32.95±3.22; TL
			24h, early deambulation and free fluids on the operation day, followed by		Dey 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 6: FTL = 45.66±8.5; TL = 60.48±10.54. Preoperative CD3: FTL = 56.21±2. TL = 55.15±2.65; CD3 Day 1: FTL + 78.13±2.13; CC Day 3: FTL = 60.35±3.02* TL = 47.6 2.34; CD3 Day 5: FTL = 51.92±2.55 48.21±2.29; Preoperative CD4: F1 33.02±2. Day 1: FTL = 27.05±2.34; TL = 27.95±5.59; CC Day 1: FTL = 27.05±2.34; TL =
			24h, early deambulation and free fluids on the operation day, followed by		Dey 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 6: FTL = 45.65±6.5; TL = 60.43±10.54. Preopensive CD3: FTL = 56.21±2.1 TL = 55.15±2.65; CD3 Day 1: FTL - 47.8±13.27; TL = 46.13±2.10 Day 3: FTL = 80.35±3.02; TL = 47.8 2.34; CD3 Day 5: FTL = 51.92±2.05; FTL = 30.35±3.22; TL = 32.95±3.59; CD Day 1: FTL = 77.05±2.34; TL = 27.9 3.07±0.20 Day 3: FTL = 28.09±2.13 2.80.54±2.19; CD4 Day 5: FTL = 38.09±2.13
			24h, early deambulation and free fluids on the operation day, followed by		Day 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 6: FTL = 45.65±8.25; TL = 90.43±10.54. Preoperative CO3: FTL = 55.21±2.7 TL = 55.15±2.65; CD3 Day 1: FTL 47.81±3.27; TL = 46.13±2.13; CD Day 3: FTL = 50.35±3.02; TL = 47.62 3:4; CO3 Day 5: FTL = 51.92±2.65 = 49.21±2.29; Preoperative CO4: FTL = 30.92±2.25 Day 1: FTL = 27.05±2.34; TL = 27.3 3:1; CO4 Day 3: FTL = 28.02±2.31 2:20.55±2.15; CO4 Day 5: FTL = 30.2±2.31 = 28.05±2.15; CO4 Day 5: FTL = 30.2±2.31
			24h, early deambulation and free fluids on the operation day, followed by		Day 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 5: FTL = 45.65±8.5; TL = 60.48±10.54. Preoperative CD3: FTL = 55.21±2.3 TL = 55.15±2.65; CD3 Day 1: FTL 47.8±13.27; TL = 46.13±2.13; CC Day 3: FTL = 90.35±3.002; TL = 47.8 2.34; CD3 Day 5: FTL = 51.9±2.2.55 49.21±2.29; Preoperative CD4: FT 33.02±3.22; TL = 23.99±3.59; CD by 1: FTL = 70.5±2.34; TL = 27.33; CD4 Day 3: FTL = 29.05±2.14; TL = 27.33; CD4 Day 3: FTL = 29.02±2.34; CD4 Day 5: FTL = 30.2±2.34; CD4 Day 5: FTL = 30.2±2.34; TL = 29.02±2.34; CD4 Day 5: FTL = 30.2±2.34; TL = 29.02±2.34; TL = 29.02±2.34; TL = 20.2±2.34; TL = 20.05±2.34; TL
			24h, early deambulation and free fluids on the operation day, followed by		Dey 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 6: FTL = 45.65±6.5; TL = 60.43±10.54. Preopensive CD3: FTL = 56.2±2.2; TL = 55.15±2.65; CD3 Day 1: FTL 47.8±13.27; TL = 46.13±2.25; CD Day 3: FTL = 50.35±3.02; TL = 47.6 2.34; CD3 Day 5: FTL = 51.92±2.65; F3.02±3.22; TL = 32.95±3.59; CD Day 1: FTL = 70.5±2.34; TL = 27.9 3.02±3.22; TL = 32.95±3.59; CD Day 1: FTL = 20.2±3.47; TL = 27.9 3.01; CD4 Day 3: FTL = 20.9±3.47; TL = 20.2±2.47; TL = 20.02±2.44; Postoperation CD4/CD6 ratio: FTL = 12.4±4.0.44; TL = 22.9.02±2.44; Postoperation CD4/CD6 ratio: FTL = 12.4±4.0.44; TL = 22.9.02±2.44; Postoperation CD4/CD6 ratio: FTL = 12.4±4.0.44; TL = 22.9.02±2.44; Postoperation CD4/CD6 ratio: FTL = 12.4±4.0.44; TL = 22.9.02±2.44; Postoperation CD4/CD6 ratio: FTL = 12.4±4.0.44; TL = 22.9.02±2.44; Postoperation CD4/CD6 ratio: FTL = 12.4±4.0.44; TL = 22.9.02±2.44; Postoperation CD4/CD6 ratio: FTL = 12.4±4.0.44; TL = 22.9.02±2.44; Postoperation CD4/CD6 ratio: GTL = 12.4±4.0.44; TL = 22.9.02±2.44; Postoperation CD4/CD6 ratio: GTL = 12.4±4.0.44; TL = 22.9.02±2.44; Postoperation CD4/CD6 ratio: GTL = 12.4±4.0.44; TL = 22.9.02±2.44; Postoperation CD4/CD6 ratio: GTL = 12.4±4.0.44; TL = 24.04; TL = 24
			24h, early deambulation and free fluids on the operation day, followed by		Day 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 6: FTL = 45.65±8.25; TL = 90.43±10.54. Preoperative CO3: FTL = 55.21±2.1 TL = 55.15±2.65; CD3 Day 1: FTL 47.81±3.27; TL = 46.13±2.13; CD Day 3: FTL = 50.35±3.02: TL = 47.62 3:4; CO3 Day 5: FTL = 51.92±2.26 = 49.21±2.29; Preoperative CO4: FTL = 33.02±3.22; TL = 32.95±3.59; CD Day 1: FTL = 27.05±2.34; TL = 27.3 3:1; CD4 Day 3: FTL = 28.02±2.31 2:20.53±2.19; CD4 Day 5: FTL = 30.2±2.31 2:24: TL = 29.02±2.41. Postoperat CD4/CD6 ratio: FTL = 1.24±0.24; TL = 22.05±2.25; CD4/CD8 ratio day 1: FTL = 1.05±0.22; TL = 0.04±0.19; CD4/CD8
			24h, early deambulation and free fluids on the operation day, followed by		Day 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 5: FTL = 45.56±5.5; TL = 60.48±10.54. Preoperative CD3: FTL = 55.21±2.3 TL = 55.15±2.65; CD3 Day 1: FTL = 75.21±2.3 TL = 55.15±2.65; CD3 Day 1: FTL = 75.21±2.3 TL = 50.35±3.02; TL = 47.8 2.34; CD3 Day 5: FTL = 50.35±3.02; TL = 47.8 2.34; CD3 Day 5: FTL = 51.92±2.25 TL = 23.95±3.59; CD Day 1: FTL = 27.05±2.34; TL = 27.05±2.34
			24h, early deambulation and free fluids on the operation day, followed by		Dey 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 buy 6: FTL = 45.65±6.5; TL = 60.43±10.54. Preopensive CD3: FTL = 56.2±2.2; TL = 55.15±2.65; CD3 Day 1: FTL 47.8±13.27; TL = 46.13±2.25; CD3 Day 5: FTL = 56.2±2.25; CD3 Day 5: FTL = 56.2±2.25; CD3 Day 5: FTL = 51.92±2.25; F3.02±3.22; TL = 32.95±3.59; CD Day 1: FTL = 70.6±2.34; TL = 27.93; CD3 Day 5: FTL = 80.2±2.44; TL = 27.93; CD4 Day 5: FTL = 30.2±2.44; TL = 27.93; CD4 Day 5: FTL = 30.2±2.44; TL = 27.93; CD4 Day 5: FTL = 30.2±2.44; TL = 27.93; CD4 Day 5: FTL = 30.2±2.44; TL = 27.93; CD4 Day 5: FTL = 30.2±2.44; Day 5: FTL = 1.93±0.25; CD4/CD8 ratio day 1: FTL = 1.14±0.24; TL = 1.03±0.21; CD4/CD8 ratio day 5: FTL = 1.14±0.24; TL = 1.03±0.21; CD4/CD8 ratio day 5: FTL = 1.14±0.24; TL = 1.03±0.21; CD4/CD8 ratio day 5: FTL = 1.14±0.24; TL = 1.03±0.21; CD4/CD8 ratio day 5: FTL = 1.14±0.24; TL = 1.03±0.21; CD4/CD8 ratio day 5: FTL = 1.14±0.24; TL = 1.03±0.21; CD4/CD8 ratio day 5: FTL = 1.03±0
Tian et al., 2020	Laproscopic	ERAS Group	24h, early deambulation and free fluids on the operation day, followed by	Preoperative, postoperative	Day 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Day 6: FTL = 45.65±6.25; TL = 60.43±10.54. Preoperative CD3: FTL = 55.21±2.1 TL = 55.15±2.65; CD3 Day 1: FTL = 47.81±2.13; CD Day 3: FTL = 50.35±3.02±7.1=47.82 3:4; CD3 Day 5: FTL = 51.92±2.65 49.21±2.29; Preoperative CD4: FTL = 51.92±2.65 49.21±2.29; Preoperative CD4: FTL = 33.02±3.23; TL = 27.93±3.02±3.22; TL = 32.95±3.59; CD Day 1: FTL = 27.05±2.34; TL =
Tian et al., 2020	Laproscopic Gastractomy	ERAS Group (EG) and	24h, early deambulation and free fluids on the operation day, followed by regular diet on the other day. Postoperative: Patient education,		Day 3: FTL = 70.58±12.13; TL = 95.26±13.35; IL-6 bay 5: FTL = 45.65±8.25; IL-6 00.48±10.54. Preoperative CD3: FTL = 55.21±2.3 TL = 55.15±2.65; CD3 Day 1: FTL = 75.21±2.3 TL = 55.15±2.65; CD3 Day 1: FTL = 75.21±2.3 TL = 50.35±3.02; TL = 47.8 2.34; CD3 Day 5: FTL = 51.92±2.65 3.04; CD3 Day 5: FTL = 51.92±2.65 3.07±3.22; TL = 23.99±3.59; CD Day 1: FTL = 27.05±2.31; TL = 28.99±3.59; CD Day 1: FTL = 27.05±2.31; TL = 28.90±2.13 2.0.65±2.19; CD4 Day 5: FTL = 30±2.13 2.0.65±2.19;
Tian et al., 2020		(EG) and	24h, early deambulation and free fluids on the operation day, followed by regular diet on the other day. Postoperative: Patient education, organ function evaluation and	day 1, postoperative day 4	Dey 3: FTL = 70:58±12.13; TL = 95:26±13.55; IL-6 bay 5: FTL = 45:56±5.5° TL = 60:43±10.54. Preopensive CD3: FTL = 56:21±2.3° TL = 55:55±2.65; CD3 Dey 1: FTL 47:81±3.27; TL = 45:13±2.7° TL = 45:13±2.25; CD3 Dey 3: FTL = 50:35±3.02; TL = 47:6. 2.34; CD3 Dey 5: FTL = 51:92±2.65; CD3 Dey 1: FTL = 71:92±2.65; CD3 Dey 1: FTL = 72:75±2.25; CD3 Dey 1: FTL = 72:75±2.25; TL = 72:75±2.2
Tian et al., 2020		(EG) and Conventional	24h, early deambulation and free fluids on the operation day, followed by regular diet on the other day. Postoperative: Patient education, organ function evaluation and pre-rehabilitation, 6h fasting and 2h	day 1, postoperative day 4 and postoperative day 6.	Dey 3: FTL = 70.58±12.13; TL = 95.26±13.55; IL-6 Dey 5: FTL = 45.65±6.5; TL = 96.43±10.54. Preopensive CD3: FTL = 55.21±2.3 TL = 55.15±2.65; CD3 Dey 1: FTL 47.8 2.34; CD3 Dey 5: FTL = 45.12±2.50; Dey 3: FTL = 56.35±3.02; TL = 47.6 2.34; CD3 Dey 5: FTL = 51.92±2.65; 30.2±3.22; TL = 32.95±3.59; CD Dey 1: FTL = 27.05±2.34; TL = 27.9 3.01; CD4 Dey 3: FTL = 28.02±2.13, 2.05±2.19; CD4 Dey 3: FTL = 30.2±2.13, 2.05±2.19; CD4 Dey 3: FTL = 30.2±2.11, 1.22±0.25; CD4/CD6 ratio day 1: FT 1.05±0.22; TL = 0.94±0.19; CD4/CD7 ratio day 3: FTL = 1.11±0.24; TL = 1.03±0.21; CD4/CD6 ratio day 5: FTL 1.14±0.20; TL = 1.05±0.22; The results were not quantitative available in absolute numbers, or a graphical representation. On the
Tian et al., 2020		(EG) and	24h, early deambulation and free fluids on the operation day, followed by regular diet on the other day. Postoperative: Patient education, organ function evaluation and	day 1, postoperative day 4	95 26±13.55; IL-6 Day 5: FTL = 46.56±8.25; TL = 60.43±10.54. Prespensive CO3: FTL = 55.21 ± 2.7 TL = 55.15 ± 2.65; CD3 Day 1: FTL 47.81 ± 3.27; TL = 61.3 ± 2.15; CD3 Day 1: FTL = 61.35 ± 3.02; TL = 47.81 ± 2.34; CD3 Day 5: FTL = 51.92 ± 2.65; E4.21 ± 2.29; Prespensive CD4: FTL = 33.02 ± 3.22; TL = 32.95 ± 3.59; CD Day 1: FTL = 70.05 ± 2.34; TL = 27.13 ± 2.05; E4.21 ± 2.05; E4.

ERAS Recommendations Characteristics

The ERAS recommendations varied but commonly included preoperative patient education, a six-hour fasting period, and carbohydrate-rich liquids up to two hours before surgery. Intraoperative measures focused on fluid restriction, body temperature maintenance, and multimodal anesthetic strategies, including epidural anesthesia in four studies. Postoperative care emphasized early mobilization across all studies.

Sampling and Inflammatory Markers

Blood samples were collected at various times: six studies (16-20, 22) during the intraoperative period, one study (17) 12 hours post-surgery, 4 studies (18-21) collected on the first postoperative day, 3 studies (16, 18, 20) collected on the 3rd postoperative day, 2 studies (17, 19) collected on the 4th postoperative day and 2 studies (18, 20) on the 5th postoperative day, and Tian et al. (19) was the only study to analyze samples on the 6th postoperative day. Inflammatory markers analyzed included white blood

count (WBC) $^{(19-22)}$, C-reactive protein (CRP) $^{(18-21)}$, albumin $^{(16, 21)}$, neutrophil/lymphocyte ratio (NLR) $^{(16, 21, 22)}$, total protein (TP) $^{(16)}$, cortisol $^{(20)}$, interleukin-6 (IL-6) $^{(18, 20)}$, immunoglobulin (Ig) G, IgM, IgA $^{(17)}$, T lymphocytes $^{(17, 18)}$, natural killer (NK) cells $^{(17)}$, procalcitonin $^{(19)}$, and platelet count $^{(22)}$ (Table 3).

Table 3. - Assessment of the ERAS protocol and the inflammatory markers analyzed.

Author/ Years	Was the randomizatio n sequence adequately generated?	Was allocation adequately concealed?	Was there blinding of participants?	Was there blinding of the caregiver?	Was there blinding of data collectors?	Was there blinding of staticians?	Was there blinding of outcome assessors?	Was loss to follow-up (missing outcome data) infrequent?*	Are reports of the study free of suggestion of selective outcome reporting?	Was the study apparently free of other problems that could put it at a risk of bias?
Xu et al. 2015	Definetely yes	Probably yes	Probably not	Definetely not	Probably yes	Probably yes	Definetely yes	Definetely not	Probably yes	Definetely yes
Wang et al. 2012	Definetely yes	Probably yes	Probably not	Definetely not	Probably yes	Probably yes	Definetely yes	Definetely not	Probably yes	Definetely yes
Peng et al. 2021	Definetely yes	Probably yes	Probably not	Definetely not	Probably yes	Probably yes	Definetely yes	Definetely not	Probably yes	Definetely yes
Mari et al. 2016	Definetely yes	Probably yes	Probably not	Definetely not	Probably yes	Probably yes	Definetely yes	Definetely not	Probably yes	Definetely yes

Risk of Bias in Studies

Randomized studies showed adequate random sequence generation and allocation concealment. Blinding of participants was achieved, but not for surgical staff due to the nature of the procedures. We did not consider this at high risk of bias because those outcomes cannot be influenced by the participants. Blinding of caregivers was considered at high risk due to the impossibility to hide surgical technique from them. Blinding of data collectors, statisticians, and outcome assessors were considered at low risk of bias in all studies. There were no studies reporting total loss to follow-up above the 10% threshold nor above 5% between groups. Therefore, loss to follow-up was considered as low risk of bias (Table 4).

Table 4. - Risk of bias randomized studies.

Author year	Do exposed individuals represent the general population?	Was certainty of exposure adequate?	Was selection of non- exposed cohort adequate?	Demonstr ation that outcome of interest was not present at start of study?	Comparab ility of cohorts (age)	Comparab ility of cohorts (other controlled factors)	Assessme nt of Outcome	Adequate follow-up time	Loss to follow-up	
Categories	SELF	SELECTION (1 POINT PER QUESTION)				COMPARABILITY (1 POINT PER QUESTION) OUTCOMES (1 POINT PER QUESTION)				
Tian, 2020	yes	yes	no	yes	yes	yes	yes	no	yes	
Liu, 2020r	yes	yes	yes	yes	yes	yes	yes	no	no	
Jalloun, 2020	yes	yes	yes	yes	yes	probably yes	yes	yes	yes	

Non-randomized studies showed critical. Bias due to confounding was considered critical in two studies (19, 21), and considered to be serious in one study(19), because they did not correct the adequate non-exposed cohort groups for confounding factors. Bias in selection of participants was considered to be serious in all observational studies (16, 19, 21), because selection was offered, and not encompassing all the patients. Bias in classification of exposures was considered moderate in three studies(16, 19, 21) because information was self-reported. Bias due to missing data was considered serious in all studies(16, 19, 21) due to the design of the studies (Table 5 and 6).

Table 5. - Risk of bias non-randomized studies.

		Quality a	ssessment			Sumr			
							Anticipat ef	Certa	
N∘ of participants (studies) Follow-up in days	Risk of bias	Inconsisten cy	Indirectness	Imprecisio n	Publication bias	Average (CI 95%)	Control 1	ERAS	in estin ates
CRP posto	perative day	three						,	
220 (2) 5 days	No serious limitations	Serious limitations ¹	Serious limitations²	Serious imprecision ³	Undetected		Mean CRP reduction was -	Average 25.98 less (-47.05 less to -4.91 less).	⊕00 0 VERY

RP postope	erative day five							
220 (2) 5 days	No serious limitations	Serious limitations¹	Serious limitations ²	Serious imprecision ³	Undetected	Mean CRP reduction was -28.50	Average - 28.50 less CRP (- 55.46 less to -1.53 less)	⊕0 0 VER LOV

Table 6. – Assessment of GRADE.

¹⁻ There was a serious limitation related to inconsistency (I 2 >50%).

²⁻There was a serious limitation related to indirectness(not a clinical outcome).

³⁻There was a serious limitation related to imprecision (rated down twice due to low number of events and wide confidence intervals).

C-reactive protein (CRP): has been investigated in two observational studies (19, 21) and two RCTs (18, 20). The studies included 1,322 patients in the retrospective cohorts^(19, 21) and 303 patients in two RCTs ^(18, 20). It found significantly lower levels of CRP in ERAS group when compared with standard on postoperative day (POD) 1, 3, and 5. All retrospective studies found lower plasma concentrations of CRP after laparoscopy when compared to open surgery. Jelloun et al. (21), 2020, including 296 patients, found an increase in CPR count of 24.1% in the ERAS group and an increase of 80.6% in the control group (p < 0.001). Tian et al. $^{(19)}$, 2020, including 1026 patients, found no significant reduction of CRP in the ERAS group compared to the control group. Mari et al. (20), 2016, including 140 patients, found that ERAS protocol significantly reduced the rise slope of CRP on postoperative days, 1, 3, and 5 (p<0,05) compared to the control group. Results from two RCTs, including 220 participants, found a significant reduction on the rising slope of C-reactive protein on postoperative day three in the ERAS group compared to the control group (MD -25.98, 95%CI -47.05, -4.91; p=0.02; I²=96%). Certainty of evidence was considered very low due to imprecision (wide confidence interval and low number of patients), inconsistency (from high heterogeneity) and indirectness (Figure 2).




Figure 2. - Comparison of CRP on postoperative days three between ERAS and control groups.

Results from two RCTs^(18, 20), including 220 participants, found a significant reduction on the rising slope of C-reactive protein on postoperative day five in the ERAS group compared to the control group (MD -28.50 95% CI -55.46, -1.53; p=0.04; I²=98%). Certainty of evidence was considered very low due to imprecision (wide confidence interval and low number of patients), inconsistency (from high heterogeneity) and indirectness (Figure 3).




Figure 3. - Comparison of CRP on postoperative days five between ERAS and control groups.

White blood cell count (WBC): two observational^(19, 21) and two RCT ^(20, 22) analyzed this inflammatory marker. They found significant reduction of WBC in the ERAS group compared to control on POD 1,3, and 5. Jaloun et al.⁽²¹⁾, 2020, including 296 patients, found an increase on WBC count of 42.7% in the ERAS group and an increase of 72.9% in the control group. Time required for the WBC count to normalize was significantly shorter in the ERAS group than in the control group (p \leq 0.001). Tian et al. ⁽¹⁹⁾, 2020, including 1,026 patients. Although results were not quantitatively available in absolute numbers, a graphic representation suggests that WBC did not increase as much in the ERAS group as it did in the control. Both randomized control trials by Peng et al. ⁽²²⁾, including 130 patients, and Mari et al. ⁽²⁰⁾, including 140 patients, found no significant reduction of WBC in the ERAS group compared to the control group.

Interleukin-6 (IL-6): Two RCTs ^(18, 20) evaluated the impact of the ERAS protocol on patients undergoing laparoscopic surgery and the IL-6 marker. A total population of 303 patients, both studies found significantly lower levels of IL-6 on POD 3 after ERAS protocol groups versus standard groups.

DISCUSSION

This scoping review evaluates the impact of Enhanced Recovery After Surgery (ERAS) recommendation measures during the perioperative period on inflammatory markers in patients undergoing laparoscopic surgery. It aims to elucidate consistent findings, recognize knowledge gaps, and suggest directions for future research on both existing and novel inflammatory markers.

The initial studies following the conceptualization of ERAS by Kehlet et al.⁽⁶⁾ focused predominantly on morbidity, mortality, and surgical complications, rather than on the quantitative assessment of inflammatory markers. It took 13 years from the inception of this concept for the first study analyzing the influence of ERAS on inflammatory markers in laparoscopic surgeries to be published.

Laparoscopic colorectal surgery was the most examined procedure, covered in five of the seven included studies. These studies collectively analyzed a total of 2,047 patients, with 891 undergoing colorectal procedures. The largest study, by Tian et al.⁽¹⁹⁾, involved 1,026 patients and examined laparoscopic gastrectomy.

White blood cell count, and C-reactive protein were the most frequently assessed markers, each studied in four investigations. Notably, critical inflammatory markers such as tumor necrosis factoralpha and alpha 1-acid glycoprotein were absent from the studies reviewed, representing a significant gap in the literature. Markers such as neutrophil gelatinase-associated lipocalin (NGAL) and N-terminal pro B-type natriuretic peptide (NT-proBNP), which indicate organ damage, were also not evaluated.

All reviewed studies reported benefits of the ERAS recommendations over standard care, notably in reducing the surgical stress response, as evidenced by lower levels of IL-6, CRP, and WBCs. Moreover, a trend towards fewer postoperative complications was observed in ERAS patients, although statistical significance was achieved in only one study.

Our findings support the literature showing a beneficial impact of ERAS recommendations, particularly noted in significant reductions of CRP levels on postoperative days three and five (Figures 2 and 3). However, the overall certainty of this evidence remains very low due to issues with precision, consistency, and directness.

This review's strengths lie in its methodical approach, including a comprehensive search, systematic selection, and rigorous bias assessment, independently replicated by multiple reviewers. Additionally, the GRADE approach was employed to enhance the reliability of evidence evaluation. Conversely, the primary limitations stem from high variability in study outcomes, insufficient blinding of surgical teams, and the reliance on a limited number of small-scale studies, which collectively restrict the precision and applicability of the findings.

This scoping review highlights the need for additional randomized controlled trials (RCTs) to more precisely determine the effects and validate the impact of Enhanced Recovery After Surgery (ERAS)

recommendations on inflammatory markers in laparoscopic surgery. The preliminary findings suggest that the implementation of ERAS guidelines may significantly reduce inflammatory markers, potentially leading to enhanced recovery outcomes for patients undergoing laparoscopic procedures. However, due to the limited number of studies and their small sample sizes, the certainty of these findings remains very low, emphasizing the importance of further high-quality research to provide more definitive evidence and refine clinical practice guidelines.

FUNDING: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

REFERENCES

- 1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-44.
- 2. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7.
- 3. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res. 2006;4(4):221-33.
- 4. Paik KY, Lee IK, Lee YS, Sung NY, Kwon TS. Clinical implications of systemic inflammatory response markers as independent prognostic factors in colorectal cancer patients. Cancer Res Treat. 2014;46(1):65-73.
- 5. Engelman RM, Rousou JA, Flack JE, 3rd, Deaton DW, Humphrey CB, Ellison LH, et al. Fast-track recovery of the coronary bypass patient. Ann Thorac Surg. 1994;58(6):1742-6.
- 6. Kehlet H, Mogensen T. Hospital stay of 2 days after open sigmoidectomy with a multimodal rehabilitation programme. Br J Surg. 1999;86(2):227-30.
- 7. Brindle M, Nelson G, Lobo DN, Ljungqvist O, Gustafsson UO. Recommendations from the ERAS® Society for standards for the development of enhanced recovery after surgery guidelines. BJS Open. 2020;4(1):157-63.
- 8. Lord JM, Midwinter MJ, Chen YF, Belli A, Brohi K, Kovacs EJ, et al. The systemic immune response to trauma: an overview of pathophysiology and treatment. Lancet. 2014;384(9952):1455-65.
- 9. Carli F. Physiologic considerations of Enhanced Recovery After Surgery (ERAS) programs: implications of the stress response. Can J Anaesth. 2015;62(2):110-9.
- 10. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 10. England 2019. p. Ed000142.

- 11. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467-73.
- 12. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.
- 13. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.
- 14. Guyatt GH, Schünemann HJ, Djulbegovic B, Akl EA. Guideline panels should not GRADE good practice statements. J Clin Epidemiol. 2015;68(5):597-600.
- 15. Morgan RL, Thayer KA, Santesso N, Holloway AC, Blain R, Eftim SE, et al. A risk of bias instrument for non-randomized studies of exposures: A users' guide to its application in the context of GRADE. Environ Int. 2019;122:168-84.
- 16. Liu X, Wang Y, Fu Z. Impact of enhanced recovery after surgery on postoperative neutrophil-lymphocyte ratio in patients with colorectal cancer. J Int Med Res. 2020;48(6):300060520925941.
- 17. Xu D, Li J, Song Y, Zhou J, Sun F, Wang J, et al. Laparoscopic surgery contributes more to nutritional and immunologic recovery than fast-track care in colorectal cancer. World J Surg Oncol. 2015;13:18.
- 18. Wang G, Jiang Z, Zhao K, Li G, Liu F, Pan H, et al. Immunologic response after laparoscopic colon cancer operation within an enhanced recovery program. J Gastrointest Surg. 2012;16(7):1379-88.
- 19. Tian YL, Cao SG, Liu XD, Li ZQ, Liu G, Zhang XQ, et al. Short- and long-term outcomes associated with enhanced recovery after surgery protocol vs conventional management in patients undergoing laparoscopic gastrectomy. World J Gastroenterol. 2020;26(37):5646-60.
- 20. Mari G, Crippa J, Costanzi A, Mazzola M, Rossi M, Maggioni D. ERAS Protocol Reduces IL-6 Secretion in Colorectal Laparoscopic Surgery: Results From a Randomized Clinical Trial. Surg Laparosc Endosc Percutan Tech. 2016;26(6):444-8.
- 21. Jaloun HE, Lee IK, Kim MK, Sung NY, Turkistani SAA, Park SM, et al. Influence of the Enhanced Recovery After Surgery Protocol on Postoperative Inflammation and Short-term Postoperative Surgical Outcomes After Colorectal Cancer Surgery. Ann Coloproctol. 2020;36(4):264-72.
- 22. Peng J, Dong R, Jiao J, Liu M, Zhang X, Bu H, et al. Enhanced Recovery After Surgery Impact on the Systemic Inflammatory Response of Patients Following Gynecological Oncology Surgery: A Prospective Randomized Study. Cancer Manag Res. 13. New Zealand: © 2021 Peng et al.; 2021. p. 4383-92.